Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption stops the synthesis of nucleotides needed for DNA and RNA production, thereby reducing the proliferation of rapidly dividing cells, including immune and cancer cells.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard dosing can be provided here; the prescriber will set the appropriate regimen.

Metoject is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and may affect the infant.

To order Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Metoject (methotrexate) is an oral/ injectable antimetabolite, whereas alternatives for rheumatoid arthritis include biologic agents such as TNF‑alpha inhibitors. Methotrexate is generally less expensive and has a long safety record, but biologics may be chosen when patients do not respond adequately to methotrexate or need faster disease control.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Once removed from refrigeration, use according to the manufacturer’s stability guidelines.

Metoject is given by subcutaneous injection. The healthcare professional prepares the dose using aseptic technique and injects it into the subcutaneous tissue, typically in the abdomen, thigh or upper arm, following the prescriber’s instructions.

Serious risks include severe liver toxicity, pulmonary fibrosis or pneumonitis, life‑threatening infections due to immunosuppression, bone‑marrow failure (aplastic anemia) and renal impairment. Patients should be monitored regularly for signs of these conditions and report any new symptoms promptly.

Metoject should not be used by pregnant women, individuals with severe liver or kidney disease, patients with active infections, or those who have known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with pre‑existing blood‑cell disorders.